UNLABELLED: Background In vitro proliferative and differentiation potential of mesenchymal stromal cells generated from CD271(+) bone marrow mononuclear cells (CD271-mesenchymal stromal cells) has been demonstrated in several earlier and recent reports. In the present study we focused, in addition to proliferative and differentiation potential, on in vitro and in vivo immunosuppressive and lymphohematopoietic engraftment-promoting potential of these mesenchymal stromal cells compared to bone marrow-derived mesenchymal stromal cells generated by plastic adherence (plastic adherence-mesenchymal stromal cells). DESIGN AND METHODS: We set up a series of experimental protocols in order to determine the phenotype of CD271-mesenchymal stromal cells, and their clonogenic, proliferative, differentiation and immunosuppressive potential. The potential of CD271-mesenchymal stromal cells to improve the engraftment of CD133(+) hematopoietic stem cells at co-transplantation was evaluated in immunodeficient NOD/SCID-IL2Rgamma(null) mice. RESULTS: In vitro studies demonstrated that CD271-mesenchymal stromal cells differentiate along adipogenic, osteogenic and chondrogenic lineages (trilineage potential), produce significantly higher levels of cytokines than plastic adherence-mesenchymal stromal cells, and significantly inhibit the proliferation of allogeneic T-lymphocytes in mixed lymphocyte reaction assays. Elevated levels of prostaglandin E(2), but not nitric monoxide, mediated the majority of this immunosuppressive effect. In vivo studies showed that CD271-mesenchymal stromal cells promoted significantly greater lymphoid engraftment than did plastic adherence-mesenchymal stromal cells when co-transplanted with CD133(+) hematopoietic stem cells at a ratio of 8:1 in immunodeficient NOD/SCID-IL2Rgamma(null) mice. They induced a 10.4-fold increase in the number of T cells, a 2.5-fold increase in the number of NK cells, and a 3.6-fold increase in the number of B cells, indicating a major qualitative difference between these two mesenchymal stromal cell populations. Conclusions Our results indicate that CD271 antigen provides a versatile marker for prospective isolation and expansion of multipotent mesenchymal stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. The co-transplantation of such cells together with hematopoietic stem cells in patients with hematologic malignancies may prove valuable in the prevention of impaired/delayed T-cell recovery and graft-versus-host disease.
UNLABELLED: Background In vitro proliferative and differentiation potential of mesenchymal stromal cells generated from CD271(+) bone marrow mononuclear cells (CD271-mesenchymal stromal cells) has been demonstrated in several earlier and recent reports. In the present study we focused, in addition to proliferative and differentiation potential, on in vitro and in vivo immunosuppressive and lymphohematopoietic engraftment-promoting potential of these mesenchymal stromal cells compared to bone marrow-derived mesenchymal stromal cells generated by plastic adherence (plastic adherence-mesenchymal stromal cells). DESIGN AND METHODS: We set up a series of experimental protocols in order to determine the phenotype of CD271-mesenchymal stromal cells, and their clonogenic, proliferative, differentiation and immunosuppressive potential. The potential of CD271-mesenchymal stromal cells to improve the engraftment of CD133(+) hematopoietic stem cells at co-transplantation was evaluated in immunodeficient NOD/SCID-IL2Rgamma(null) mice. RESULTS: In vitro studies demonstrated that CD271-mesenchymal stromal cells differentiate along adipogenic, osteogenic and chondrogenic lineages (trilineage potential), produce significantly higher levels of cytokines than plastic adherence-mesenchymal stromal cells, and significantly inhibit the proliferation of allogeneic T-lymphocytes in mixed lymphocyte reaction assays. Elevated levels of prostaglandin E(2), but not nitric monoxide, mediated the majority of this immunosuppressive effect. In vivo studies showed that CD271-mesenchymal stromal cells promoted significantly greater lymphoid engraftment than did plastic adherence-mesenchymal stromal cells when co-transplanted with CD133(+) hematopoietic stem cells at a ratio of 8:1 in immunodeficient NOD/SCID-IL2Rgamma(null) mice. They induced a 10.4-fold increase in the number of T cells, a 2.5-fold increase in the number of NK cells, and a 3.6-fold increase in the number of B cells, indicating a major qualitative difference between these two mesenchymal stromal cell populations. Conclusions Our results indicate that CD271 antigen provides a versatile marker for prospective isolation and expansion of multipotent mesenchymal stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. The co-transplantation of such cells together with hematopoietic stem cells in patients with hematologic malignancies may prove valuable in the prevention of impaired/delayed T-cell recovery and graft-versus-host disease.
Authors: Pieternella S In 't Anker; Sicco A Scherjon; Carin Kleijburg-van der Keur; Willy A Noort; Frans H J Claas; Roelof Willemze; Willem E Fibbe; Humphrey H H Kanhai Journal: Blood Date: 2003-08-15 Impact factor: 22.113
Authors: Pieternella S in 't Anker; Willy A Noort; Sicco A Scherjon; Carin Kleijburg-van der Keur; Alwine B Kruisselbrink; Rutger L van Bezooijen; Willem Beekhuizen; Roelof Willemze; Humphrey H H Kanhai; Willem E Fibbe Journal: Haematologica Date: 2003-08 Impact factor: 9.941
Authors: Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick Journal: Mol Biol Cell Date: 2002-12 Impact factor: 4.138
Authors: Helen Karlsson; Sujith Samarasinghe; Lynne M Ball; Berit Sundberg; Arjan C Lankester; Francesco Dazzi; Mehmet Uzunel; Kanchan Rao; Paul Veys; Katarina Le Blanc; Olle Ringdén; Persis J Amrolia Journal: Blood Date: 2008-04-28 Impact factor: 22.113
Authors: Selim Kuçi; Johannes T Wessels; Hans-Jörg Bühring; Karin Schilbach; Michael Schumm; Gabriele Seitz; Jürgen Löffler; Peter Bader; Paul G Schlegel; Dietrich Niethammer; Rupert Handgretinger Journal: Blood Date: 2002-09-19 Impact factor: 22.113
Authors: Israel M Barbash; Pierre Chouraqui; Jack Baron; Micha S Feinberg; Sharon Etzion; Ariel Tessone; Liron Miller; Esther Guetta; Dov Zipori; Laurence H Kedes; Robert A Kloner; Jonathan Leor Journal: Circulation Date: 2003-08-04 Impact factor: 29.690
Authors: Yoshitaka Iso; Krithika S Rao; Charla N Poole; A K M Tarikuz Zaman; Ingrid Curril; Burton E Sobel; Jan Kajstura; Piero Anversa; Jeffrey L Spees Journal: Stem Cells Date: 2014-03 Impact factor: 6.277
Authors: Zyrafete Kuçi; Julia Seiberth; Hatixhe Latifi-Pupovci; Sibylle Wehner; Stefan Stein; Manuel Grez; Halvard Bönig; Ulrike Köhl; Thomas Klingebiel; Peter Bader; Selim Kuçi Journal: Haematologica Date: 2013-08-23 Impact factor: 9.941
Authors: Maria Teresa González-Garza; Delia E Cruz-Vega; Alejandro Cárdenas-Lopez; Rosa Maria de la Rosa; Jorge E Moreno-Cuevas Journal: Am J Stem Cells Date: 2018-06-01
Authors: Heike Wegmeyer; Ann-Marie Bröske; Mathias Leddin; Karin Kuentzer; Anna Katharina Nisslbeck; Julia Hupfeld; Kornelius Wiechmann; Jennifer Kuhlen; Christoffer von Schwerin; Carsten Stein; Saskia Knothe; Jürgen Funk; Ralf Huss; Markus Neubauer Journal: Stem Cells Dev Date: 2013-06-22 Impact factor: 3.272
Authors: Anne Marie Josephson; Vivian Bradaschia-Correa; Sooyeon Lee; Kevin Leclerc; Karan S Patel; Emma Muinos Lopez; Hannah P Litwa; Shane S Neibart; Manasa Kadiyala; Madeleine Z Wong; Matthew M Mizrahi; Nury L Yim; Austin J Ramme; Kenneth A Egol; Philipp Leucht Journal: Proc Natl Acad Sci U S A Date: 2019-03-20 Impact factor: 11.205